Explores tumor immune evasion, drug delivery challenges, and nanoparticle strategies in cancer treatment, including the impact of checkpoint inhibitors and hydrogels.
Covers the decline of cancer death rates, conventional and targeted anticancer drugs, surgical oncology, radiotherapy, chemotherapy, resistance mechanisms, and the history of targeted drugs and EGFR targeting.
